Citations

Showing 10 of 108083 citations.

A new flortaucipir PET biomarker based on graph theory for early detection of CTE in former American football players
Protas, Hillary , Luo, Ji , Alosco, Michael L. , Adler, Charles, Balcer, Laura J. , Bernick, Charles , Banks, Sarah J. , Coleman, Michael J. , Mariani, Megan, McKee, Ann C. , Palmisano, Joseph , Peskind, Elaine R. , Johnson, Keith A. , Reiman, Eric M. , Su, Yi‐Chang , Chen, Kewei , Au, Rhoda , Barr, William , Dodick, David W. , Katz, Douglas I. , Marek, Kenneth , McClean, Michael D , Mez, Jesse , II, Robert W. Turner , Wethe, Jennifer V. , Rabinovici, Gil D. , Tripodis, Yorghos , Cummings, Jeffrey L. , Shenton, Martha E. , Stern, Robert A.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.068936 Get It

AbstractBackgroundChronic traumatic encephalopathy (CTE) is a neurodegenerative disease that is characterized by perivascular foci of phosphorylated tau (p‐tau) notably in the depths of sulci, with varying patterns in the cerebral cortex. Prior studies show elevated flortaucipir (FTP) PET binding in former American professional football players(PRO). However, the association of p‐tau with clinical measures remains unclear using regional FTP SUVR as early signs of CTE related tau pathology. Graph theory (GT) takes advantages of the spatial variability in p‐tau load and allows the integration of regional measures to define GT based measures. Here we examine the GT based measures in two CTE cohorts to evaluate their utility in assessing p‐tau related pathology in CTE.MethodThe graph procedure was optimized in FTP PET images in a group of 26 PRO with reported cognitive and/or behavorial symptoms and 30 asymptomatic controls without a history of traumatic brain injury (the DETECT Study) and identified the GT measure, entorhinal tau strength, as the target metric with the best group separation between PRO and controls. The optimized graph procedures were then applied to the DIAGNOSE CTE Research Project dataset (99 former PRO, 51 former college football players [COL], and 52 controls without exposure to repetitive head impacts [CTL]) and we examined entorhinal tau strength’s ability to differentiate the exposure groups and relationship to consensus based diagnoses of Traumatic Encephalopathy Syndrome (TES), the clinical syndrome associated with CTE.ResultEntorhinal tau strength was significantly different among the three exposure groups (p=0.0001) similar to regional SUVR measures (Figure 1). Regional SUVR did not differentiate players (PRO+COL) with and without TES, while entorhinal tau strength approached although did not reach significance (Figure 2). Entorhinal tau strength is the only FTP measure that showed significant differences (p=0.006) between those players with cognitive impairment and players without (Figure 3).ConclusionWhile there is still considerable overlap in between‐group measurements, GT based entorhinal tau strength, is potentially more sensitive in detecting tau changes in players with and without TES. Additional studies are necessary to clarify the value of this new measure in detecting underlying CTE pathology.
Sex and APOE‐ε4 carrier effects on early‐onset Alzheimer’s disease pathology
Logan, Paige E. , Nemes, Sára , Aisen, Paul , Eloyan, Ani , Fagan, Anne M. , Foroud, Tatiana M., Gatsonis, Constantine , Hammers, Dustin B. , Kramer, Joel H. , Koeppe, Robert, Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Sha, Sharon, Carrillo, Marı́a C., Apostolova, Liana G. , Iaccarino, Leonardo , Mundada, Nidhi S. , Joie, Renaud La , Dage, Jeffrey L. , Hammers, Dustin B , Jack, Clifford R. , Saykin, Andrew J. , Toga, Arthur W. , Vemuri, Prashanthi , Atri, Alireza , Day, Gregory S. , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Sha, Sharon J. , II, Robert W. Turner , Womack, Kyle , Rabinovici, Gil D. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.068743 Get It

AbstractBackgroundPreviously, we found that female sex is associated with greater pathology burden in early‐onset Alzheimer’s disease (EOAD) in the Longitudinal EOAD Study (LEADS). Here, we have expanded our analyses by adding APOE‐ε4 carrier status as a further predictor of EOAD pathologic burden.MethodWe included 180 EOAD LEADS participants with available APOE genotype, Flortaucipir PET, Florbetaben PET, and MRI data. Demographic and biomarker differences were analyzed using ANOVA. EOAD participants were split by sex and APOE‐ε4 carrier status. Box plots were created in R and a voxel‐wise multiple linear regression in SPM12 yielded statistical brain maps of gray matter density (GMD), amyloid and tau burden.ResultCompared to males, EOAD females showed significantly greater global amyloid uptake (mean SUVR, p=0.002) and greater tau SUVR in the MetaROI, Braak 3&4 and 5&6 regions (p=0.0007, p=0.001, p=0.01, resp., Table 1). Female APOE‐ε4 carriers showed greater tau SUVR in Braak regions 1&2 than female non‐carriers (p<0.01, Figure 2B). Male APOE‐ε4 carriers showed trend‐level thinner entorhinal cortex than male non‐carriers (p=0.06, Figure 1). Interestingly however, femaleAPOE‐ε4 non‐carriers showed greater global amyloid SUVR than female carriers (p<0.01, Figure 2A). Further, APOE‐ε4 non‐carriers showed significantly thinner medial temporal cortices than carriers in both sexes (M, p<0.05; F, p<0.01). Male APOE‐ε4 non‐carriers also showed significantly lower mean cortical thickness than male carriers (p<0.05, Figure 1). Female APOE‐ε4 non‐carriers showed trend‐level lower mean cortical thickness than female carriers (p=0.06, Figure 1). The FWE corrected SPM12 maps showed significantly greater GM atrophy in the right temporal lobe and greater amyloid burden in a right lateralized occipitoparietal pattern in female APOE‐ε4 non‐carriers compared to female carriers. Further, male APOE‐ε4 non‐carriers showed greater tau uptake in the left frontal lobe than male carriers (Figure 3).ConclusionThese results suggest that APOE‐ε4 non‐carrier status is associated with greater atrophy, amyloid and tau deposition in EOAD. This might be due to the presence of other strong genetic drivers of disease pathology in EOAD.
A novel machine learning technique using resting‐state EEG to assess and monitor cognitive impairment
Quirk, Colin , Brookshire, Geoffrey , Gerrol, Spencer, Caselli, Richard J. , Lucero, Ché , Wu, Yunan , Merrill, David A.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.068143 Get It

AbstractBackgroundMonitoring changes in cognitive impairment is an important aspect of care for aging patients. Traditionally, this is done with pen‐and‐paper assessments such as the Mini‐Mental State Exam (MMSE). EEG is a low‐cost and widely available neurophysiology tool that provides a data‐rich measure of brain health, but signal complexity has limited its impact. Advances in machine learning bring new possibilities to decode those complex signals and leverage EEG in patient care. Here, we engineer novel EEG features for assessing brain health with the [Banded Fractal Variability] (BFV) technique. We use [BFV] and other EEG metrics to assess patients’ cognitive function via a continuous score (a [Cognitive Impairment Index], or [CII]). We validate the diagnostic value of the EEG features by comparing our model against reduced models lacking the EEG features.MethodThe patient sample (N=97, mean (sd) age = 69.1 (11.0), 52.6% female) was collected at the Pacific Brain Health Center. Diagnostic categories included subjective cognitive impairment (n=44), mild cognitive impairment (n=26), and dementia (n=27). Mixed disease (AD, DLB, FTD, vascular, diabetes) was common in the impaired sample, and 39.6% were diagnosed with AD. We developed a continuous [CII] model trained on patients’ MMSE scores (range = 11 to 30, mean = 26.6) using a gradient boosting model with [Banded Fractal Variability] and other EEG features computed from clinical wake EEGs. Model development and testing took place within a rigorous nested cross‐validation (NCV) procedure to prevent overfitting. Performance was compared to reduced (no‐EEG features) models using the non‐parametric Wilcoxon sign‐rank test.ResultThe approach showed a Mean Absolute Error of 1.98 (sd = 0.28) across 5 test folds in the NCV outer loops, significantly outperforming both the baseline intercept‐only model (p = 0.031) and the demographics (age and years of education) model (p = 0.031).ConclusionThese preliminary results suggest that our [CII] derived from machine‐learning and quantitative EEG using [BFV] is a viable approach to assess and track patients’ cognitive impairment regardless of disease status across all impairment levels, raising the possibility that a brief EEG scan could shed light on patient health normally accessible only through extensive cognitive and neuropsychological testing.
[18F]PI‐2620 PET in four‐repeat tauopathies: a preliminary study
Soleimani‐Meigooni, David N. , Thomas, Wesley P. , Vento, Stephanie , Heuer, Hilary W. , Ljubenkov, Peter A. , Chen, Miranda , Iaccarino, Leonardo, Pantelyat, Alex, Baker, Suzanne L. , Boxer, Adam L. , Brendel, Matthias , Rojas, Julio C. , Iaccarino, Leonardo , Joie, Renaud La , Mundada, Nidhi S. , Boeve, Bradley F. , Grossman, Murray , Dickerson, Bradford Clark , Irwin, David J. , Litvan, Irene , Tartaglia, Maria Carmela , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067974 Get It

AbstractBackgroundThere is a critical need for tau PET radiotracers that accurately detect non‐Alzheimer’s disease (AD) tau pathology. We aim to evaluate [18F]PI‐2620 PET tracer retention in patients with non‐AD, 4R tau‐related clinical syndromes, including progressive supranuclear palsy (PSP) with Richardson’s syndrome (PSP‐RS) and with predominant parkinsonism (PSP‐P), corticobasal syndrome (CBS), and nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA).Method38 participants underwent amyloid and [18F]PI‐2620 PET (Table 1). 5 mCi ± 10% of [18F]PI‐2620 was administered. [18F]PI‐2620 PET SUVR images were generated using an inferior cerebellar gray matter reference from PET data acquired 30‐60 minutes post‐injection. Mean SUVR values were extracted from each participant in neuroanatomical structures that have elevated tau burden in PSP and CBS due to corticobasal degeneration (regions of interest in Table 2). Comparison between each diagnostic group and healthy controls (HCs) was performed using a one‐tailed, independent‐samples t‐test. Spearman correlation was used to evaluate the relationship between tracer binding (SUVR) and disease severity (PSP rating scale) in patients with PSP‐RS.ResultPatients with PSP‐RS had increased tracer retention in the left globus pallidus internus and externus, left subthalamic nucleus, and left dorsolateral prefrontal cortex compared to HCs (all p < 0.05). CBS and nfvPPA patients did not have increased tracer retention at any ROIs compared to HCs, but there were low numbers of patients in these groups (Table 2, Figures 1‐3). PSP rating scale values did not correlate with tracer binding in PSP‐RS (no correlations in any regions, rs < 0.44, p > 0.05 uncorrected).Conclusion[18F]PI‐2620 PET 30‐60 minute SUVR images may have limited ability to distinguish PSP from HCs, especially on visual read, and tracer uptake did not correlate with PSP disease severity. Other post‐injection PET acquisition windows (e.g., 30‐40 minute SUVR, 0‐60 minute DVR) will be evaluated to determine if they can maximize differences between PSP and HCs. A limitation of this preliminary study is the modest number of patients and controls, with most controls provided from a different study. Additional participants are being scanned in the multicenter 4RTNI study to understand the utility of this tracer as a neuroimaging biomarker for 4R tauopathies.
Genetic contribution to grey matter network disruptions and Alzheimer disease cerebrospinal fluid markers
Dicks, Ellen , Tomassen, Jori , Kate, Mara ten , Teunissen, Charlotte E. , Scheltens, Philip , Barkhof, Frederik , Braber, Anouk den , Visser, Pieter Jelle , Tijms, Betty M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067768 Get It

AbstractBackgroundGrey matter covariance networks become disrupted early in Alzheimer’s disease (AD), when amyloid starts aggregating, and before the onset of irreversible atrophy. However, the precise relationship of grey matter network breakdown and the AD pathophysiological process remains unclear. Here, we studied to what extent shared familial (genes and family environment) or environmental factors unique to a twin contribute to these relationships in a sample of older monozygotic twins with intact cognition.MethodFrom the EMIF‐AD PreclinAD study we included monozygotic twins who had at least an MRI scan (n=197) and CSF available (n=124). We assessed the upper limit of genetic contribution to grey matter network measures (size, degree, connectivity density, clustering, path length, small‐world measures) with within‐twin pair correlations. Associations between CSF AD markers (Aβ42/40, t‐tau, p‐tau) and other markers related to AD pathophysiology (neurogranin, Aβ38, Aβ40, BACE1) with grey matter network disruptions were assessed with linear mixed models. Twin analyses (cross‐twin cross‐trait, twin difference analyses) were used to assess the contribution of shared familial and/or unique environmental factors to these associations.ResultTwenty individuals (16%) had abnormal CSF Aβ42/40 levels. Grey matter network measures were highly correlated within twin pairs (r=0.54‐0.97; all p<0.001, Fig.1), suggesting a moderate to strong genetic background. Across the whole sample, more abnormal Aβ42/40 ratios were moderately related to lower connectivity density (β±SE = 0.176±0.09, p=0.055, Fig.2). The strongest associations with grey matter network measures were observed for t‐tau and p‐tau levels (range β=‐0.344‐0.182), followed by Aβ production markers (Aβ38, Aβ40, BACE1) (range β=‐0.202‐0.165). We observed no relationships between neurogranin and grey matter network measures. Cross‐twin cross‐trait analyses showed that levels for t‐tau, p‐tau and Aβ38 in one twin were associated with grey matter network measures in their co‐twin (r=‐0.27 to ‐0.21; p range=0.02 to 0.07, Fig.3). Within‐pair differences in BACE1 were related to within‐pair differences in normalized path length values (r=0.35; p=0.01; Fig.4).ConclusionOur results suggest a shared familial background for the relationship of grey matter network disruptions and AD‐related processes as measured in CSF. In addition, unique environmental factors influencing BACE1 may also affect grey matter network disruptions.
Neurodegenerative Pathways in Alzheimer's Disease Subtypes
Wheatley, Sophia , Muehlboeck, J‐Sebastian, Levin, Fedor , Mohanty, Rosaleena , Ferreira, Daniel , Grothe, Michel J. , Westman, Eric

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067749 Get It

AbstractBackgroundBiological heterogeneity in Alzheimer’s disease (AD) has been observed and described as subtypes in measures of neurodegeneration (e.g., hypometabolism and atrophy). However, the relationship between these AD subtypes have not been studied. Thus, we aimed to compare and identify pathways associated with hypometabolism‐based and atrophy‐based subtypes.MethodCross‐sectional FDG‐PET and MRI scans from 173 amyloid‐positive AD individuals and 120 amyloid‐negative cognitively normal control individuals from the ADNI were included. Subtypes were identified in each neuroimaging modality by random forest hierarchical clustering using FDG‐PET uptake (measuring hypometabolism) and MRI volumes (measuring atrophy) in cortical and subcortical regions. We performed cross‐modal comparisons of atrophy patterns in hypometabolism‐based subtypes and hypometabolism patterns in atrophy‐based subtypes. To identify neurodegenerative pathways corresponding to each subtype, we used event‐based modelling to predict sequential progression of abnormality in hypometabolism and atrophy across brain regions (hippocampus, AD signature, frontal, posterior areas).ResultClustering revealed four hypometabolism‐based (two relatively limbic‐predominant: 25.7%, 19.8% and two relatively cortical‐predominant: 25.7%, 28.6%) and three atrophy‐based (diffuse: 18.7%, relatively limbic‐predominant: 28.6%, minimal: 52.6%) subtypes of AD with distinct spatial patterns and demographic and clinical characteristics. Cross‐modally, we found comparable AD‐typical atrophy patterns (involving the hippocampus and temporal regions) across the four hypometabolism‐based subtypes and comparable AD‐typical hypometabolism patterns (involving the retrosplenial cortex) across the three atrophy‐based subtypes. Event‐based modelling showed that each hypometabolism‐based subtype was associated with a unique sequential progression of regional hypometabolism, but not regional atrophy (sequence always initiated with frontal atrophy across all subtypes). Similarly, each atrophy‐based subtype was associated with a unique sequential progression of regional atrophy, but not regional hypometabolism (sequence always initiated with hypometabolism in AD signature areas across all subtypes).ConclusionOur findings suggest that hypometabolism‐based and atrophy‐based AD subtypes are not interchangeable. We identified unique metabolic and atrophy pathways specific to each subtype, which supports the notion that neurodegeneration manifests and progresses differentially across subtypes of AD. Despite being measures of neurodegeneration, hypometabolism and atrophy may not share the same extent of heterogeneity, bearing a complex multimodal relationship. Disentangling such relationships and combining complementary biomarkers to investigate heterogeneity could aid personalized treatment of AD.
Amyloid independent pathways have an impact on longitudinal tau deposition
Lesnick, Timothy G. , Przybelski, Scott A. , Graff‐Radford, Jonathan, Lowe, Val J. , Petersen, Ronald C. , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067607 Get It

AbstractBackgroundAmyloidosis‐driven tau deposition has been a significant focus of imaging research in Alzheimer’s disease (AD). However, the 3R/4R tau seen in AD can be observed in the transentorhinal/entorhinal regions (Braak I/II) in the absence of amyloidosis. The underlying drivers of this phenomenon are not well understood. Our goal was to examine amyloid‐independent pathways of longitudinal Tau‐PET SUVR progression in the entorhinal cortex (ERC) using a broad range of risk and protective factors.MethodWe identified 449 participants from the population‐based sample of Mayo Clinic Study of Aging >50 years old with baseline amyloid PET and at least two serial tau PET scans (mean number of scans=2.3; mean follow‐up time=3.2 years). Using an amyloid SUVR cut‐point of 1.48, we categorized participants into A+ (n=167; mean age=77.5 years; 56% male; baseline ERC tau=1.20; 83% cognitively unimpaired) and A‐ (n=282; mean age=67.5; 56% male; baseline ERC tau=1.07; 92% cognitively unimpaired). We used an ERC tau SUVR cut‐point of 1.21 to determine T+. We fit mixed effects and growth curve models with age, sex, baseline amyloid, risk factors (midlife activities, sleep, stress, education/occupation, cardiovascular metabolic conditions) as predictors and longitudinal ERC tau as the outcome. We fit separate models in A‐, A+, and all participants.ResultsFor models of all participants and A+ participants, the only predictors of higher rates of ERC tau deposition were increasing age and amyloid SUVR (p<0.05). In the A‐ models (figure below), amyloid SUVR and age were predictors of baseline, but not longitudinal ERC tau. However, a greater number of cardiovascular metabolic conditions predicted a higher rate of ERC tau accumulation (0.007 (0.002), p<0.05). Only 13% of the 23 A‐T+ participants were APOE4 carriers (compared to 31% in the overall sample), suggesting the role of non‐APOE4 pathways to tau deposition.ConclusionOur results support previous evidence that significant amyloidosis is causal to higher rates of tau deposition. However, in those without significant amyloidosis, cardiovascular metabolic conditions predicted higher rates of ERC tau accumulation. Further work is warranted to investigate the mechanisms through which genetics, comorbidities, and lifestyle may play a role in early tau deposition.
Amyloid PET in the Lewy Body disease continuum
Przybelski, Scott A. , Lesnick, Timothy G. , Gunter, Jeffrey L. , Jain, Manoj , Miyagawa, Toji , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff‐Radford, Jonathan , St, Erik K, Graff‐Radford, Neill R. , Petersen, Ronald C. , Lowe, Val J. , Diaz‐Galvan, Patricia , Schwarz, Christopher G. , Senjem, Matthew L. , Jack, Clifford R. , Min, Hoon-Ki Paul , Knopman, David S. , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.067319 Get It

AbstractBackgroundβ‐amyloid plaques, a pathological hallmark of Alzheimer’s disease, are common in dementia with Lewy bodies (DLB). However, little is known about when β‐amyloid levels increase throughout the Lewy body disease (LBD) continuum, from an early prodromal stage of isolated REM sleep behavior disorder (iRBD), to a stage of mild cognitive impairment‐Lewy bodies (MCI‐LB), and finally DLB. Our objective was to investigate β‐amyloid deposition throughout the LBD continuum, as well as the influence of sex and APOE ε4 status, as potential factors contributing to Alzheimer’s disease pathological changes.MethodPatients with iRBD (n=24), MCI‐LB (n=62), and DLB (n=82) from the Mayo Clinic Alzheimer’s Disease Research Center and Center for Sleep Medicine were included. β‐amyloid levels were measured by Pittsburgh compound B (PiB) PET and global cortical standard uptake value ratio (SUVR) was calculated. Global cortical PiB SUVR values from each clinical group were compared to each other and to cognitively unimpaired individuals (CU; n=100) balanced on age and sex from the Mayo Clinic Study of Aging (MCSA). Clinical groups were compared using ANCOVA after adjusting by age.ResultMCI‐LB and DLB patients had significantly higher global cortical PiB SUVR than CU participants, while PiB SUVR in iRBD patients was comparable to that of CU participants (Figure 1). DLB patients also had significantly higher global cortical PiB SUVR compared to iRBD patients (p=0.004). In MCI‐LB and DLB, global cortical PiB SUVR was higher in APOE ε4 carriers compared to APOE ε4 non‐carriers (p<0.001), and women had higher global cortical PiB SUVR compared to men (p=0.024).ConclusionIn this cross‐sectional study, β‐amyloid pathology gradually increased throughout the clinically defined LBD continuum. Whereas β‐amyloid levels are comparable to cognitively unimpaired individuals in iRBD, a significant elevation in β‐amyloid levels coincides with cognitive impairment observed in MCI‐LB and DLB. Specifically, women and APOE ε4 carriers tend to have higher β‐amyloid levels than men and APOE ε4 non‐carriers. These findings have important implications for targeting patients within the LBD continuum, who may benefit from amyloid modifying therapies.
Interpreting blood‐based biomarker results in heterogeneous populations with multiple co‐morbidities
Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.066904 Get It

AbstractBackgroundA major benefit of the use of blood‐based biomarkers in screening for Alzheimer’s disease (AD) pathology, or diagnosing AD dementia, is that the collection of blood is less invasive and costly than cerebrospinal fluid or neuroimaging markers. Blood biomarkers are also more feasible and available at the primary care levels, where most individuals will present with cognitive symptoms. However, most studies examining blood‐based biomarkers of amyloid, phosphorylated tau, or neurodegeneration for screening or diagnosis have been conducted in neurology or memory clinics. Patients that reach these clinics often have less comorbidities and are younger than those seen and followed in primary care. Thus, there is a need to assess the utility of these blood‐biomarkers in diverse, community‐based cohorts of older ages, with multiple comorbidities, and with brain co‐pathologies (i.e., cerebrovascular disease).MethodUsing examples from the Mayo Clinic Study on Aging and other community‐based studies, we will synthesize the impact of demographics, comorbidities, and co‐pathologies on blood measures of amyloid‐beta, phosphorylated tau, neurofilament light chain (NfL), total tau, and glial fibrillary acid protein (GFAP). Additional discussion will focus on how these factors may impact cut‐points and the interpretation of the blood biomarkers across the AD clinical spectrum, as well as potential methods to better elucidate the biomarker results for clinical care.ResultBlood measures of amyloid‐beta, phosphorylated tau, NfL, total tau, and GFAP are differentially affected by age and sex and some comorbidities (e.g., chronic kidney disease, stroke, myocardial infarction, diabetes, body mass index). Although adjusting for covariates has been a method used in some research studies, adjustment will not work on an individualized level for patients seen in primary care. Different cutpoints may be needed based on age and the presence or absence of specific comorbidities. In addition, when interpreting the results for diagnosis and prognosis, co‐occurring co‐pathologies (e.g., cerebrovascular disease) must be considered.ConclusionSeveral studies have shown the promise of blood‐based biomarkers for screening and diagnosing AD in memory clinics. However, several considerations and steps are needed before these blood biomarkers can be implemented for use at the population level and in primary care.BackgroundWhen and how to communicate effectively the results of genetic and biomarker based prediction, detection, and quantification of the brain substrates of dementia involve important ethical and legal issues critical for precision medicine. AGREEDementia is an open working group that focuses on informed discussions and development of educational material to support communication and use of this information.MethodMembers attend two meetings monthly via videoteleconference. One meeting is a targeted working group that focuses on the following: 1. People with Symptoms, 2. People without Symptoms, 3. Research, 4. Ethics/Healthcare Law, 5. Diversity. Members also attend a monthly “all hands” meeting where they receive updates from other groups, partner organizations, and hear presentations on emerging research and resources.ResultOver the past few years AGREEDementia has produced several collaborative papers, webinars, and decision tools for people considering undergoing biomarker testing that will be discussed. Membership continues to grow to over 120 though level of involvement varies. The group is largely comprised of academic researchers (76%) including neurologists, neuropsychologists, clinical trial coordinators, ethicists, and healthcare lawyers. The second largest subgroup was from advocacy groups and stakeholders (18%) and 6% are students. Collaborations with other organizations including the NIA, Alzheimer’s Association/ISTAART, the Lewy Body Dementia Association, Association for Frontotemporal Dementia, and Cohen Veterans Bioscience greatly enrich the group by publicizing conferences and collaborating on papers and products. The Alzheimer’s & Dementia Outreach, Recruitment & Engagement at NIA also disseminates decision tools and other materials. Over time, the stakeholder group developed from an audience providing consultation to a creative force that pioneered a program to support people with cognitive dysfunction attending AAIC and other scientific conferences. The Diversity workgroup was added in order to mentor and teach research staff in sensitive outreach to diverse cohorts. The ongoing, monthly, lecture series and links to all these materials are hosted at a website, AGREEDementia.com.ConclusionWith controversies around how best to integrate biomarker and genetic information into clinical care, when to share research data with the public, and implement novel biomarker‐based therapies, AGREEDementia has provided an open forum for all to visit and consult.
Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration
Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Preboske, Gregory M., Farlow, Martin R. , Fagan, Anne M. , Fitzpatrick, Colleen , Salloway, Stephen , Perrin, Richard J. , Graff‐Radford, Neill R. , Koeppe, Robert, Chui, Helena C., Mori, Hiroshi , Johnson, Keith A., Greenberg, Steven M. , Chhatwal, Jasmeer P. , Investigators, DIAN, Schultz, Stephanie A. , Joseph‐Mathurin, Nelly , Kantarci, Kejal , Jack, Clifford R. , Hassenstab, Jason , Jucker, Mathias , Morris, John C. , Xiong, Chengjie , Karch, Celeste M. , Levey, Allan I. , Gordon, Brian A. , Schofield, Peter William , McDade, Eric , Xiong, Chengjie , Cruchaga, Carlos , Allegri, Ricardo , Fox, Nick C. , Goate, Alison , Noble, James M. , Chui, Helena C. , Berman, Sarah , Sánchez‐Valle, Raquel , Lee, Jae‐Hong , Rosa-Neto, Pedro , Benzinger, Tammie L.S. , Sohrabi, Hamid R. , Martins, Ralph N. , Schultz, Aaron P. , Bateman, Randall J. , Johnson, Keith A. , Sperling, Reisa Anne , Investigators, DIAN

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.066715 Get It

AbstractBackgroundWhite matter (WM) injury visible on MRI is a common finding in Alzheimer’s disease (AD) and is often attributed to small vessel ischemic changes secondary to increased systemic vascular risk. Increased WM injury has been associated with the progression of Autosomal Dominant AD (ADAD), though ADAD pathogenic variant carriers are relatively young and may not have elevated vascular risk factors. We hypothesized that WM injury in ADAD may reflect worsening of cerebral amyloid angiopathy (CAA) and neurodegeneration. Here we examine this hypothesis using cross‐sectional and longitudinal data from the Dominantly Inherited Alzheimer Network observational study (DIAN).MethodMRI data from ADAD pathogenic variant carriers (n=223) and non‐carriers (n=136) were used in the present study (Table 1). We extracted FreeSurfer‐based WM lesion (WML) volume from T1‐weighted images (hypointensities). Cortical microbleed (CMB) burden was assessed visually on susceptibility weighted/T2*‐weighted gradient echo images by experienced radiologists (blineded to the mutation status) at the Mayo Clinic in Rochester. Linear regression models compared WML volume at baseline in people with and without CMB. Linear mixed effect models assessed the relationships between longitudinal WML and both CMBs and FreeSurfer‐based total gray matter (GM) volume. Models were corrected for age and estimated years to symptom onset (EYO).ResultGreater baseline WML volume was seen in ADAD carriers vs. non‐carriers, particularly close to the age of estimated symptom onset. Baseline WML volume was greater in carriers with CMBs compared to those without (t=2.9, p=0.003, Figure 1). Longitudinal increase in WML amongst ADAD pathogenic variant carriers with CMBs was estimated to be 214 mm3/year greater than that amongst carriers without CMBs (t=4.1, p<0.001, Figure 2). Independent of this CMB effect, decreasing GM volume was strongly associated with increasing longitudinal WML volume (t=‐6.2, p<0.001, Figure 3). Similar analyses in the non‐carrier group yielded no significant findings.ConclusionConsistent with prior reports, WML volume was increased in ADAD pathogenic variant carriers. However, the results here suggest WML in ADAD may not solely be due to small vessel ischemic changes, but rather may be a result of worsening CAA and more rapid neurodegeneration.